References
- Tefferi A. Annual Clinical Updates in Hematological Malignancies: a continuing medical education series: polycythemia vera and essential thrombocythemia: 2011 update on diagnosis, risk-stratification, and management. Am J Hematol. 2011;86:292–301.
- Landolfi R, Di Gennaro L. Pathophysiology of thrombosis in myeloproliferative neoplasms. Haematologica. 2011;96:183–6.
- Landolfi R, Di Gennaro L, Falanga A. Thrombosis in myeloproliferative disorders: pathogenetic facts and speculation. Leukemia. 2008;22:2020–8.
- Landolfi R, Di Gennaro L, Barbui T, de Stefano V, Finazzi G, Marfisi RM, et al.. European Collaboration on Low-Dose Aspirin in Polycythemia Vera (ECLAP) leukocytosis as a major thrombotic risk factor in patients with polycythemia vera. Blood. 2007;109:2446–52.
- Carobbio A, Thiele J, Passamonti F, Rumi E, Ruggeri M, Rodeghiero F, et al.. Risk factors for arterial and venous thrombosis in WHO-defined essential thrombocythemia: an international study of 891 patients. Blood. 2011;117:5857–9.
- Landolfi R, Di Gennaro L. Prevention of thrombosis in polycythemia vera and essential thrombocythemia. Haematologica. 2008;93:331–5.
- Marchioli R, Finazzi G, Landolfi R, Kutti J, Gisslinger H, Patrono C, et al.. Vascular and neoplastic risk in a large cohort of patients with polycythemia vera. J Clin Oncol. 2005;23:2224–32.
- Landolfi R, Marchioli R, Kutti J, Gisslinger H, Tognoni G, Patrono C, et al.. Efficacy and safety of low-dose aspirin in polycythemia vera. N Engl J Med. 2004;350:114–24.
- Cazzola M. Risk assessment in myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms. Haematologica. 2011;96:349–52.
- Aguayo A, Armillas-Canseco FM, Martínez-Baños D. Antiangiogenesis in myelodysplastic syndrome. Curr Cancer Drug Targets. 2011;11:1044–52.
- Yang X, Brandenburg NA, Freeman J, Salomon ML, Zeldis JB, Knight RD, et al.. Venous thromboembolism in myelodysplastic syndrome patients receiving lenalidomide: results from postmarketing surveillance and data mining techniques. Clin Drug Investig. 2009;29:161–71.
- Weiss Smith S, Sato M, Gore SD, Baer MR, Ke X, McNally D, et al.. Erythropoiesis-stimulating agents are not associated with increased risk of thrombosis in patients with myelodysplastic syndromes. Haematologica. 2012;97:15–20.